India’s first COVID-19 vaccine Covaxin trial starts at AIIMS Delhi
The first phase of human clinical trials of COVAXIN, India’s first indigenous vaccine begins at AIMS, New Delhi
New Delhi: The first human clinical trial of coronavirus vaccine Covaxin started at AIIMS, New Delhi, on Friday (July 24). The first shot of the vaccine was given to a 30-year-old man.
According to India Today, the man will be kept in observation for two hours in the hospital. Then he will be sent home and be monitored for the next seven days, sources in the AIIMS said.
About 3,500 people have registered to take part in the trial of the vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Covaxin is being jointly developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). It recently received the nod for human clinical trials from the Drugs Controller General of India (DCGI).
In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.